<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>DISEASE CHARACTERISTICS: MECP2-related disorders in females include classic <z:e sem="disease" ids="C0035372" disease_type="Disease or Syndrome" abbrv="RTT">Rett syndrome</z:e>, variant <z:e sem="disease" ids="C0035372" disease_type="Disease or Syndrome" abbrv="RTT">Rett syndrome</z:e>, and mild <z:e sem="disease" ids="C0751265" disease_type="Mental or Behavioral Dysfunction" abbrv="">learning disabilities</z:e>; phenotypes in males are primarily severe neonatal <z:hpo ids='HP_0001298'>encephalopathy</z:hpo> and <z:e sem="disease" ids="C0005586" disease_type="Mental or Behavioral Dysfunction" abbrv="">manic-depressive</z:e> <z:hpo ids='HP_0000709'>psychosis</z:hpo>, pyramidal signs, parkinsonian, and macro-orchidism (PPM-X) syndrome </plain></SENT>
<SENT sid="1" pm="."><plain>Classic <z:e sem="disease" ids="C0035372" disease_type="Disease or Syndrome" abbrv="RTT">Rett syndrome</z:e>, a progressive <z:e sem="disease" ids="C1535926" disease_type="Mental or Behavioral Dysfunction" abbrv="">neurodevelopmental disorder</z:e> primarily affecting girls, is characterized by apparently <z:mpath ids='MPATH_458'>normal</z:mpath> psychomotor development during the first six to 18 months of life, followed by a short period of <z:hpo ids='HP_0007281'>developmental stagnation</z:hpo>, then rapid regression in language and motor skills, followed by long-term stability </plain></SENT>
<SENT sid="2" pm="."><plain>During the phase of rapid regression, repetitive, stereotypic hand movements replace purposeful hand use </plain></SENT>
<SENT sid="3" pm="."><plain>Additional findings include fits of screaming and inconsolable crying, autistic features, panic-like attacks, <z:hpo ids='HP_0003763'>bruxism</z:hpo>, episodic <z:hpo ids='HP_0002104'>apnea</z:hpo> and/or <z:mp ids='MP_0010946'>hyperpnea</z:mp>, <z:hpo ids='HP_0002066'>gait ataxia</z:hpo> and <z:hpo ids='HP_0002186'>apraxia</z:hpo>, <z:hpo ids='HP_0001337'>tremors</z:hpo>, <z:hpo ids='HP_0001250'>seizures</z:hpo>, and acquired <z:hpo ids='HP_0000252'>microcephaly</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Atypical <z:e sem="disease" ids="C0035372" disease_type="Disease or Syndrome" abbrv="RTT">Rett syndrome</z:e> is observed increasingly as MECP2 mutations are identified in individuals previously diagnosed with clinically suspected but molecularly unconfirmed <z:e sem="disease" ids="C0162635" disease_type="Disease or Syndrome" abbrv="">Angelman syndrome</z:e>, <z:hpo ids='HP_0001249'>intellectual disability</z:hpo> with <z:hpo ids='HP_0001257'>spasticity</z:hpo> or <z:hpo ids='HP_0001337'>tremor</z:hpo>, mild <z:e sem="disease" ids="C0751265" disease_type="Mental or Behavioral Dysfunction" abbrv="">learning disability</z:e> or rarely in individuals diagnosed with <z:hpo ids='HP_0000717'>autism</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Severe neonatal <z:hpo ids='HP_0001298'>encephalopathy</z:hpo> resulting in <z:hpo ids='HP_0011420'>death</z:hpo> before age two years is the most common phenotype observed in affected males </plain></SENT>
<SENT sid="6" pm="."><plain>DIAGNOSIS/TESTING: The diagnosis of <z:hpo ids='HP_0000001'>all</z:hpo> MECP2-related disorders relies on molecular genetic testing </plain></SENT>
<SENT sid="7" pm="."><plain>Sequence analysis and deletion testing for exonic, multiexonic, and whole-gene deletions are available on a clinical basis </plain></SENT>
<SENT sid="8" pm="."><plain>The diagnosis of classic <z:e sem="disease" ids="C0035372" disease_type="Disease or Syndrome" abbrv="RTT">Rett syndrome</z:e> rests on clinical diagnostic criteria </plain></SENT>
<SENT sid="9" pm="."><plain>MANAGEMENT: Treatment of manifestations: Treatment is mainly symptomatic and multidisciplinary and should include psychosocial support for family members </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="0" ids="8871">Risperidone</z:chebi> may help in treating <z:hpo ids='HP_0000713'>agitation</z:hpo>; <z:chebi fb="9" ids="16796">melatonin</z:chebi> can ameliorate <z:hpo ids='HP_0002360'>sleep disturbances</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>Treatment of <z:hpo ids='HP_0001250'>seizures</z:hpo>, <z:hpo ids='HP_0002019'>constipation</z:hpo>, <z:hpo ids='HP_0002020'>gastroesophageal reflux</z:hpo>, <z:hpo ids='HP_0002650'>scoliosis</z:hpo>, and <z:hpo ids='HP_0001257'>spasticity</z:hpo> is routine </plain></SENT>
<SENT sid="12" pm="."><plain>Surveillance: periodic evaluation by the multidisciplinary team; regular assessment of QTc for evidence of prolongation; regular assessment for <z:hpo ids='HP_0002650'>scoliosis</z:hpo> </plain></SENT>
<SENT sid="13" pm="."><plain>Agents/circumstances to avoid: drugs known to prolong the QT interval </plain></SENT>
<SENT sid="14" pm="."><plain>GENETIC COUNSELING: MECP2-related disorders are inherited in an <z:hpo ids='HP_0001417'>X-linked</z:hpo> manner </plain></SENT>
<SENT sid="15" pm="."><plain>Over 99% are simplex cases (i.e., a single occurrence in a family), resulting from a de novo mutation, or possibly from <z:hpo ids='HP_0000005'>inheritance</z:hpo> of the disease-causing mutation from a parent who has somatic or germline mosaicism </plain></SENT>
<SENT sid="16" pm="."><plain>Rarely, a MECP2 mutation may be inherited from a carrier mother in whom favorable skewing of X-chromosome inactivation results in minimal to no clinical findings </plain></SENT>
<SENT sid="17" pm="."><plain>When the mother is a known carrier, the risk to her offspring of inheriting the MECP2 mutation is 50% </plain></SENT>
<SENT sid="18" pm="."><plain>Prenatal testing is possible in pregnancies at increased risk if the MECP2 mutation has been identified in the family </plain></SENT>
<SENT sid="19" pm="."><plain>Because of the possibility of germline mosaicism, it is appropriate to offer prenatal diagnosis to couples who have had a child with a MECP2-related disorder regardless of whether the disease-causing mutation has been detected in a parent </plain></SENT>
</text></document>